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Objective: The objective of this study was to conduct 
an economic evaluation of rofecoxib and celecoxib com-
pared with high-dose acetaminophen or ibuprofen with
and without misoprostol for patients with symptomatic
knee osteoarthritis (OA).
Methods: A decision analysis model was designed over 6
months using two measures of effectiveness: 1) number
of upper gastrointestinal (GI) adverse events averted; and
2) number of patients who achieved perceptible pain
relief. Separate analyses were conducted for all patients
and for those who did not respond to acetaminophen.
Outcome probabilities were obtained from a comprehen-
sive review of randomized controlled trials and observa-
tional studies. Costs were derived from actual resource
utilization of OA patients.
Results: In terms of averting GI events, acetaminophen
dominates the other options for an average risk patient
population. For patients who did not respond to aceta-
minophen, rofecoxib had the lowest incremental cost-
effectiveness ratio (ICER) per GI event avoided ($32,000)
relative to ibuprofen. In terms of pain control, ibuprofen
had an ICER of $610.77 per additional patient achieving
minimal perceptible clinical improvement (MPCI) relative
to acetaminophen, while rofecoxib had an ICER of
$12,000 relative to ibuprofen. For patients who did not
respond to acetaminophen and who are at high risk of
developing an adverse GI event, rofecoxib dominates
ibuprofen as the preferred alternative for both measures
of effectiveness. One-way, two-way, and probabilistic sen-
sitivity analyses established that these results were gener-
ally robust.
Conclusions: Our results suggest that for average-risk
knee OA patients, acetaminophen dominates the other
therapies in terms of cost per GI event averted. In terms
of pain relief, cost-effectiveness acceptability curves indi-
cate that if one values pain relief below $275 per patient
achieving MPCI, acetaminophen is the therapy most
likely to be optimal; between $275 and $14,150, ibupro-
fen is most likely to be optimal; and above $14,150, rofe-
coxib is most likely to be optimal.
Keywords: acetaminophen, cost-effectiveness, knee
osteoarthritis, NSAIDs, selective COX-2 inhibitors.
Address correspondence to: Sherine E. Gabriel, Health 
Sciences Research, Mayo Clinic, 200 1st Street SW,
Rochester MN 55905. E-mail: gabriel.sherine@mayo.edu
Volume 6 • Number 2 • 2003
V A L U E  I N  H E A L T H
The Cost-Effectiveness of Acetaminophen, NSAIDs, and
Selective COX-2 Inhibitors in the Treatment of Symptomatic
Knee Osteoarthritis
Celia C. Kamath, PhD, Hilal Maradit Kremers, MD, MSc, David J.Vanness, PhD,
W. Michael O’Fallon, PhD, Rosa L. Cabanela, PhD, Sherine E. Gabriel, MD, MSc
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
ABSTRACT
Introduction
It has been estimated that approximately 21 mil-
lion Americans have symptomatic osteoarthritis
(OA) [1]. Nonsteroidal anti-inﬂammatory drugs
(NSAIDs) have been the most widely used drugs to
treat OA. Approximately 70 to 75 million NSAID
prescriptions are written annually in the United
States alone, at a cost of approximately $2 billion
[2,3]. Over the past two decades, evidence docu-
menting NSAID toxicity has been overwhelming.
Notably, the majority of societal expenses attribut-
able to NSAIDs are related to the treatment of
adverse effects, particularly adverse gastrointestinal
(GI) events [4]. In fact, acetaminophen is currently
recommended as the ﬁrst-line therapy for OA of the
knee and hip according to the current treatment
guidelines for the management of OA published by
the American College of Rheumatology (ACR) [5]
and others [6], partly due to the toxicity of NSAIDs.
NSAIDs inhibit cyclooxygenase (COX)-1 and
COX-2 to varying degrees. The therapeutic effect 
of NSAIDs is derived from COX-2 inhibition, while
many of the toxic effects result from COX-1 inhi-
bition. The newer NSAIDs (e.g., celecoxib, rofe-
coxib) selectively inhibit COX-2 and have been
shown to have effective anti-inﬂammatory and
analgesic properties with fewer GI toxic effects
[7,8]. However, these drugs are considerably more
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expensive than both traditional NSAIDs [9] and
acetaminophen. Thus, there is a need to examine
their cost-effectiveness (CE).
The objective of this study is to assess the CE of
celecoxib and rofecoxib to treat symptomatic knee
OA relative to the more conventional NSAIDs
(ibuprofen) used with or without misoprostol pro-
phylaxis and relative to acetaminophen. Methods of
clinical decision analysis and economic evaluation
were used, focusing largely on the direct costs of
managing GI adverse events associated with the use
of each drug. An institutional/payer perspective to
the analysis was adopted.
Subjects and Methods
Decision Analysis Model
We developed a decision analysis model (Fig. 1)
using DATA Professional, version 4.0 (TREEAGE
Software, Williamstown, MA, USA) to compare 
the costs and outcomes of ﬁve treatment options 
for knee OA: acetaminophen (1g QID), ibuprofen
(800mg TID), ibuprofen (800mg TID) plus 
misoprostol (200mg TID), celecoxib (200mg QD),
and rofecoxib (25mg QD). The target population
for the study were patients, typically over 50 years
of age, who had radiographically identiﬁed knee
OA, for whom the above therapeutic drugs are 
indicated for pain relief. Our model was based, in
part, on a previously published decision model [10],
which reﬂected the actual management of patients
with clinically suspicious or conﬁrmed upper GI
complications, enrolled in a large-scale multicenter
trial.
Two different effectiveness outcomes were exam-
ined: effectiveness of each drug in avoiding upper
GI toxicity and in reducing pain. The ﬁrst measure
of effectiveness is deﬁned as the number of 
conﬁrmed symptomatic upper GI adverse events
averted. The second measure of effectiveness is
deﬁned as the number of patients who achieved the
minimum perceptible clinical improvement (MPCI)
from a patient’s perspective according to the
Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) pain subscale [11].
Two separate analyses were conducted. The ﬁrst
focused on all OA patients where acetaminophen,
ibuprofen, and selective COX-2 inhibitors were
included in the analysis. The second was limited 
to a subgroup of OA patients for whom aceta-
minophen failed to provide adequate pain relief
(acetaminophen nonresponders). Acetaminophen
was not included in the analysis of nonresponders.
The same outcomes were employed for both 
analyses.
The decision tree shows the sequence of events
considered in our analyses, which may occur within
6 months of the initiation of each drug (Fig. 1).
Patients using the drug may or may not experience
an adverse event in the form of a clinically con-
ﬁrmed upper GI ulcer, perforation, obstruction, 
or bleed (PUB). The term “conﬁrmed” was used to
indicate that a symptomatic ulcer was ascertained
by endoscopy or upper GI tract radiography to be
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Figure 1 Decision tree for OA treatment with pain reduction and adverse GI events averted as the effectiveness measures.
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a conﬁrmed PUB. Some of these PUBs present as
complications, namely perforation, bleeding, and/or
obstruction, necessitating either surgery or inpatient
medical management. The remaining or uncompli-
cated PUBs are symptomatic ulcers and could
require outpatient management with or without
endoscopy. We assume similar rates of resource use
to treat conﬁrmed PUBs associated with each drug.
Patients who do not experience conﬁrmed PUBs
may still be evaluated because of clinical suspicion
of a PUB or because they present with other GI
events such as dyspepsia, diarrhea, or reﬂux. Sus-
pected PUBs could require inpatient or outpatient
procedures with or without endoscopy. The other
GI events (e.g., dyspepsia) are typically treated on
an outpatient basis where a gastroprotective agent
(GPA) is generally prescribed. We assume different
rates of inpatient and outpatient procedures and
GPA use to treat suspected PUBs and other GI
events associated with each drug. Clinical outcomes
at the end of 6 months included the number of con-
ﬁrmed PUBs experienced as well as pain relief expe-
rienced with use of each drug.
We considered only short-term, nondiscounted
direct medical costs, which include the costs of 
the drugs and the costs associated with monitor-
ing and treating adverse events associated with 
each drug. The latter costs include costs associated 
with hospitalization (including surgery), outpatient
procedures and consultations, and coprescrip-
tions of GPAs. Incremental CE ratios were calcu-
lated for the nondominated options as the 
additional cost per patient achieving a unit of effec-
tiveness compared with the next less costly, non-
dominated option.
Data and Assumptions
The base-case estimates for each variable and the
ranges used for sensitivity analyses are shown in
Table 1.
Adverse GI events. The ﬁrst measure of effective-
ness was deﬁned as the number of conﬁrmed symp-
tomatic PUBs averted. PUBs include symptomatic
upper GI ulcers and ulcer complications (bleeding,
perforation, obstruction). Four groups of adverse
GI events were considered to determine the total
cost of treating adverse GI events with the use of
each drug: all conﬁrmed PUBs, complicated con-
ﬁrmed PUBs, suspected but not conﬁrmed PUBs,
and other less serious adverse GI events, each of
which have different rates of morbidity and health-
care resource utilization. Baseline probability esti-
mates (including conﬁdence intervals [CIs]) of
adverse GI events for each branch of the tree were
derived primarily from randomized controlled
trials, population-based cohort studies, several pub-
lished reports, and some unpublished reports
[12,13]. We begin with the more recent evidence for
the COX-2 inhibitor drugs versus NSAIDs.
PUB probability estimates for celecoxib were
obtained from the recently published large safety
trial CLASS study [7]. Food and Drug Administra-
tion reviews were used to extract 6 months of
overall cumulative incidence data [13]. Estimates
used for sensitivity analyses considered data from
the nonaspirin group as well as the overall PUB
rates from the CLASS study. PUB probability esti-
mates for rofecoxib were obtained from a pooled
analysis of Phase II/IIIA randomized controlled 
clinical trials in OA [14]. Six months of cumulative
incidence data as presented in the New Drug 
Application (NDA) documents were also used [15].
Sensitivity analysis estimates were derived from the
recent large safety trial in rheumatoid arthritis
VIGOR study [8] and the CLASS study, assuming
that the risk associated with rofecoxib is equal to
celecoxib. PUB probability estimates for ibuprofen
were also derived from 6 months of cumulative inci-
dence data obtained from the CLASS study [7,13].
CIs for sensitivity analysis reﬂected the range of
NSAID data available from the pooled analyses of
the rofecoxib and celecoxib randomized controlled
clinical trials [12,14,16,17]; the VIGOR study in
rheumatoid arthritis [8], assuming that the risk of
ulcer complications with ibuprofen may be compa-
rable to naproxen; and observational cohort studies
[2,18–26], which considered a variety of outcomes
mainly reﬂective of ulcer complications. Estimates
of the protective effect of misoprostol in the ibupro-
fen plus misoprostol arm were derived from the
MUCOSA study [27]. We assumed the same pro-
tective effect of misoprostol on suspected PUBs as
on conﬁrmed PUBs.
PUB probability estimates for acetaminophen
were calculated using ibuprofen data from the
CLASS study [7,13], assuming that there was no
risk of PUBs associated with acetaminophen expo-
sure compared to a relative risk of up to 4 with
ibuprofen. Recent data suggest that higher doses 
of acetaminophen also may be associated with a
higher risk of PUBs [28,29]. The higher range for
sensitivity analyses assumed a relative risk of 2 
to accommodate ﬁndings of recent observational
studies with high-dose acetaminophen [28–32].
Other GI events, which are not classiﬁed as con-
ﬁrmed PUBs (e.g., dyspepsia, abdominal pain, 
and diarrhea and referred to as GI distress in the
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Table 1 Base-case probability estimates and their ranges for sensitivity analyses over a period of 6 months 
Variable Baseline estimate (range) References
Pain efﬁcacy: probability of achieving deﬁned minimum perceptible clinical 
improvement in pain as measured on the WOMAC pain subscale
Acetaminophen .75 (.68–.8) 33–36
Ibuprofen .83 (.8–.87) 12,44
Celecoxib .79 (.73–.85) 17,35,43
Rofecoxib .86 (.82–.90) 12,35,44
GI toxicity
Probability of conﬁrmed PUB
Acetaminophen .005 (.005–.01) 7,13,14,18–20,23–26,28–32
Ibuprofen .0205 (.009–.047) 7,8,13–16,18–26,41
Celecoxib .0097 (.0065–.021) 7,13,16
Rofecoxib .0092 (.0065–.021) 8,12,14,15
Effectiveness of misoprostol vs. placebo in preventing PUB .4 (.4–.75) 27
Probability of complications from conﬁrmed PUB
Acetaminophen .002 (.002–.004) 7,13,14,18–20,23–26,28–32
Ibuprofen .0075 (.0055–.02) 7,8,13–16,18–26,41
Celecoxib .0037 (.002–.0076) 7,13,16
Rofecoxib .0020 (.002–.0076) 8,12,14,15
Effectiveness of misoprostol vs. placebo in preventing complications .16 (0–.4) 27
Probability of (unconﬁrmed) suspected PUBs*
Acetaminophen .02 (.015–.025) Assumed
Ibuprofen .022 (.0165–.0275) 27
Ibuprofen with misoprostol .0176 (.0132–.022) 27
Celecoxib .02 (.015–.025) 7
Rofecoxib .02 (.015–.025) Assumed
Probability of other GI events (e.g., dyspepsia)*
Acetaminophen .23 (.115–.23) 33–36,39,40
Ibuprofen .23 (.115–.23) 7,8,27,40
Ibuprofen with misoprostol .31 (.155–.31) 27
Celecoxib .25 (.125–.25) 7,35,37
Rofecoxib .16 (.08–.16) 8,35,38
Utilization of health-care resources
Probability of hospitalization for a complicated PUB .63 (.56–.67) 10
Probability of surgery for complicated PUB .36 (.29–.39) 10
Probability of endoscopy for uncomplicated PUB (symptomatic ulcer) .27 (.15–.35) 10
Probability of inpatient medical management of suspected PUB*
Acetaminophen .0175 (.013–.022) 40
Ibuprofen .023 (.017–.028) 10
Ibuprofen with misoprostol .023 (.017–.028) 10
Celecoxib .012 (.009–.015) Assumed
Rofecoxib .012 (.009–.015) 41
Probability of outpatient management of suspected PUB with endoscopy*
Acetaminophen .155 (.12–.19) 40
Ibuprofen .158 (.12–.20) 41
Ibuprofen with misoprostol .08 (.06–.1) 10
Celecoxib .124 (.09–.15) Assumed
Rofecoxib .124 (.09–.15) 41
Probability of outpatient management of other GI distress with GPAs*
Acetaminophen .267 (.20–.33) 40
Ibuprofen .322 (.24–.40) 41
Ibuprofen with misoprostol .12 (.09–.15) 10
Celecoxib .255 (.19–.32) Assumed
Rofecoxib .255 (.19–.32) 41
Direct costs
Medication costs ($) (cost of drug and dispensing fee [AWP price for 
prescribed dose per patient for 6 months])
Acetaminophen 30 (22.5–42) 9
Ibuprofen 50 (35–86) 9
Misoprostol 480 (320–640) 9
Celecoxib 435 (326–544) 9
Rofecoxib 435 (326–544) 9
GPAs for treatment of ulcers 355.8 (177.9–533.7) 9
GPAs for treatment of other GI events 32.4 (21.6–43.2) 9
GI toxicity monitoring costs ($)
Inpatient surgical management for conﬁrmed PUB 16,670 (14,235–19,105) (Cost data)†
Inpatient medical management for conﬁrmed PUB 12,980 (10,837–15,122) (Cost data)
Outpatient management of conﬁrmed PUB with endoscopy 1587 (1,435–1740) (Cost data)
Outpatient management of conﬁrmed PUB without endoscopy 1047 (950–1145) (Cost data)
Outpatient management of suspected PUB with endoscopy 1267 (1,150–1385) (Cost data)
Outpatient management of suspected PUB without endoscopy 709 (685–733) (Cost data)
Inpatient management of suspected PUB 11,365 (10,485–12,245) (Cost data)
Outpatient physician consult 47 (35–59) (Cost data)
*Ranges for sensitivity analyses deﬁned as 25% above and below baseline estimate.
†Mayo Clinic cost utilization data (Cost data).
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decision trees), included all adverse events classiﬁed
under the system organ class GI system disorders.
Data from the clinical trials, which included aceta-
minophen [33–36] and product monograms
[37,38], were used to derive estimates for aceta-
minophen, ibuprofen, celecoxib, and rofecoxib. For
the ibuprofen plus misoprostol arm, we assumed a
35% increase in other GI events due to misopros-
tol-related GI events (e.g., diarrhea) [27]. The fre-
quency of other GI events with ibuprofen in the
MUCOSA study was 50% lower than the CLASS
study. These data constituted the lower range for
ibuprofen in sensitivity analyses. The aceta-
minophen, celecoxib, and rofecoxib estimates were
also scaled down by a similar amount to generate
lower ranges for sensitivity analysis. The higher
range for the sensitivity analysis considered values
reported in the acetaminophen trials [33–36,39,40].
Probability estimates of resource use (endo-
scopies, upper GI radiographic series, hospitaliza-
tion, and surgery) for both complicated and
uncomplicated PUBs were derived from the
MUCOSA study [10,27]. We assumed that resource
use for conﬁrmed PUBs, which included surgical
management, hospitalization (without surgery), 
and outpatient management (with and without
endoscopy), would be the same for all drugs. Out-
patient management also included the use of GPAs
to treat ulcers. The baseline estimates refer to the
estimates for resource utilization (pooled event
rates) for all patients in the moderate and high-risk
subgroups of the MUCOSA study, while the upper
and lower sensitivity range estimates reﬂect event
rates of all patients in the misoprostol and placebo
arms, respectively.
Estimates of resource use for suspected PUBs and
other GI events such as dyspepsia and abdominal
pain were derived from the VIGOR [8] and CLASS
[7] studies and a large-scale observational study on
resource utilization of OA patients on NSAIDs
compared to acetaminophen [40]. Resource use for
suspected PUBs included hospitalization and out-
patient management (with and without GI proce-
dures) and the use of GPAs to manage these events.
Resource use and medical management for these
less serious adverse GI events were demonstrated to
be different for different drugs [41]. We conserva-
tively assumed the same rates of resource utilization
for celecoxib as rofecoxib, derived from the VIGOR
study. Resource use estimates for ibuprofen were
also obtained from the VIGOR study. Differences
in resource use between NSAIDs and aceta-
minophen were estimated based on the results of a
recent observational study [40].
Pain efﬁcacy. The second measure of effectiveness
was deﬁned as the number of patients who achieved
the MPCI with the WOMAC pain subscale [11].
The MPCI represents the difference or change on
the pain subscale associated with the smallest
change in health states detectable by the patient. A
previous study determined that MPCI is equivalent
to a change of 9.7 units on a 0 to 100 VAS
WOMAC pain scale [11].
The probability of a patient achieving MPCI was
estimated assuming a normal distribution of mean
change scores from baseline and by calculating the
probability of mean change score being less than the
MPCI, standardized by the mean and standard devi-
ation. In other words,
where F is the standard normal cumulative density
function, m is the mean change in scores from base-
line, and s is the standard deviation of mean in
change scores. This method is similar to the those
used in other CE studies [42] to assess the compar-
ative efﬁcacy of therapeutic options in a rheumatoid
arthritis population using the ACR 20 improvement
criteria.
Efﬁcacy data were extracted from NDA reviews
conducted by the FDA’s Arthritis Advisory Com-
mittee for celecoxib and rofecoxib [12,17] publica-
tions of some of these development studies included
in the NDA [43,44] and other recently published
studies that included acetaminophen [35,36]. These
data included the mean change on all efﬁcacy scores
from baseline and conﬁdence intervals or standard
deviations of these differences. Data were ab-
stracted for all of the efﬁcacy measures used in each
study. After an extensive review of completeness of
data and comparability of studies, we chose to use
the WOMAC pain subscale.
Data from Geba et al. [35] were used for cele-
coxib and rofecoxib baseline estimates. The range
for sensitivity analysis considered values calculated
from Bensen et al. [43] for celecoxib and Day et al.
[44] for rofecoxib. We also used the Day et al. study
to derive estimates for ibuprofen. We assumed that
the use of misoprostol had no impact on pain efﬁ-
cacy of ibuprofen. Data from Pincus et al. [36] and
Geba et al. [35] were used to elicit the baseline esti-
mate and range for sensitivity analysis of aceta-
minophen in terms of pain relief (Table 1).
Cost estimates. We used 5 years of institutional
billing data for patients living in a single county
Probability of achieving MPCI
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=
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who gave authorization for their data to be used 
for research purposes and who were treated at our
institution with a diagnosis of OA to determine the
cost of hospitalization and outpatient management
of conﬁrmed and suspected PUBs. To account for
inﬂationary changes in the overall cost of providing
care over the time period 1995 to 2000, we inﬂa-
tion-adjusted costs incurred each year to year 2000
levels using the All Urban Consumers U.S. City
Average Consumer Price Index for Medical Care
[45]. Because only outcomes within 6 months were
considered, no further discounting was necessary.
The robust 5% winsorized average episode costs
were used for each group. The winsorized mean is
a robust estimator of the central tendency of the dis-
tribution accounting for the presence of skewness
by replacing a proportion of extreme observations
with the value of the nearest available observation
[46]. A range of two standard errors (mean) on both
sides of the estimates was used as a range for sen-
sitivity analysis.
The cost of outpatient management of conﬁrmed
and suspected PUBs included the cost of physician
visits but did not include the cost of drugs. We
assumed that an average patient would be treated
with 40 mg of omeprazole per day for 60 days. For
the ibuprofen plus misoprostol arm, we assumed
that the treatment with misoprostol would be dis-
continued while the patient is on omeprazole.
For the cost of other GI adverse events, we
assumed that patients seek a single consultation with
a general practice physician. As a proxy for this cost,
we used year 2000 Medicare Fee Schedule average
reimbursement of $47 for CPT-499213 [47], which
is an ofﬁce or other outpatient visit for the evalua-
tion and management of an established patient with
problems of mild-to-moderate GI symptom severity,
requiring approximately 15 minutes.
Medication costs were average wholesale prices
(AWP) from the 2000 Red Book [9]. Costs of aceta-
minophen and ibuprofen were the lowest AWP for
generic brands. The baseline cost for misoprostol
was calculated at 600 mg per day. To determine the
cost of treatment with GPAs over a 6-month period,
we assumed that a patient experiencing other GI
events (e.g., dyspepsia, diarrhea) would purchase
the cheapest over-the-counter GPAs for an average
consumption for 90 days: 400 mg cimetidine QD,
20 mg famotidine QD, or 150 mg ranitidine QD.
Base-case CE analyses. We conducted an analy-
sis of incremental cost, incremental effectiveness,
and incremental CE of each option relative to the
next most costly option, using both measures of
effectiveness. These analyses were performed for all
patients and separately for acetaminophen nonre-
sponders. Effectiveness values were assumed to be
the same for both analyses.
Sensitivity analyses. One-way sensitivity analyses
were performed on every variable in the model to
examine the robustness of the results in terms of
plausible variations in variable values in the model.
Two-way and threshold sensitivity analyses were
also performed on the variables which were identi-
ﬁed as critical to the decision choice in one-way 
sensitivity analyses. In addition, we conducted a
probabilistic sensitivity analysis using the Monte
Carlo method to create 10,000 simulated trials of
the patient cohort to assess the impact of simulta-
neous variations in the distribution of important
variables around their point estimates. Using an
acceptability curve approach [48], we also assessed
how the proportion of the 10,000 simulated trials
favoring one treatment arm relative to others varies
as the monetary value placed on a unit of effective-
ness changes.
Results
Base-Case CE Analyses
Using the baseline estimates in Table 1, costs, effec-
tiveness, and incremental CE ratios for both mea-
sures of effectiveness are shown in Table 2. For a
cohort of 1000 patients, acetaminophen generated
the lowest total costs ($63,000), while ibuprofen
plus misoprostol generated the highest total costs
($556,000). Table 2 includes the base-case CE
results for all patients and for acetaminophen non-
responders with effectiveness deﬁned as adverse
events averted and percentage of patient achieving
MPCI on the WOMAC pain scale, respectively.
For all patients, when effectiveness was deﬁned
as adverse events averted, the acetaminophen
option was both the most effective (994.9 adverse
events averted in a cohort of 1000) and the least
costly ($63,000) of the ﬁve options. The other four
options both cost more and were less effective; thus,
these were “dominated” by acetaminophen. When
we replicated the analysis with effectiveness deﬁned
as the number of patients achieving MPCI on the
WOMAC pain scale, acetaminophen was again the
least costly option. Ibuprofen, the next nondomi-
nated option increased total costs by $49,000 (i.e.,
$112,000-$63,000), but also increased the pro-
bability of achieving MPCI response by 8% (or 
80 additional patients, i.e., 830–750, in a cohort 
of 1000), resulting in an incremental CE ratio of
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$610.77 per additional MPCI response relative to
acetaminophen. Rofecoxib the other nondominated
option further increased total costs and effective-
ness by $359,000 and 3%, respectively, yielding an
incremental CE ratio of approximately $12,000
over ibuprofen, the next cheaper option. The cele-
coxib and ibuprofen plus misoprostol options were
both more costly and less effective than the other
options and were therefore dominated. Another set
of analyses focused on acetaminophen nonrespon-
ders and excluded acetaminophen as an option in
the decision tree. The base-case results indicated
that for both deﬁnitions of effectiveness, ibuprofen
was the least costly ($112,000) and rofecoxib was
the most effective (990.8 adverse events averted and
860 patients achieving MPCI on the WOMAC pain
scale). Relative to ibuprofen, rofecoxib (the only
nondominated option) had an incremental CE ratio
of approximately $32,000 for every additional
adverse event averted and $12,000 for every addi-
tional patient achieving MPCI on the WOMAC
pain scale.
Sensitivity Analyses
One-way sensitivity analysis results remained
robust for both models (with and without aceta-
minophen) across the speciﬁed range of all variables
in the models. Threshold analysis on the model with
effectiveness deﬁned as GI events averted indicated
that ibuprofen is the least costly option when the
cost of acetaminophen increases beyond $80, com-
pared to baseline generic brand price of $30. Simi-
larly, when the probability of a conﬁrmed PUB from
acetaminophen is > .04 (compared to baseline esti-
mate of .005) or when the probability of a suspected
PUB from acetaminophen was over .07 (compared
to a baseline estimate of .02), ibuprofen is the least
costly option. When effectiveness was deﬁned as the
number of patients who receive perceptible pain
relief, the results were robust across all variables
except level of pain relief from acetaminophen.
Threshold analysis indicated that when aceta-
minophen provided perceptible pain relief to less
than 48% of patients, or when the probability of a
conﬁrmed PUB from acetaminophen was over .03
or a suspected PUB from acetaminophen was over
.06, ibuprofen is the least costly option. These prob-
abilities of conﬁrmed or suspected PUBs from aceta-
minophen are compatible with a relative risk of 
6.0 times above the general population [28,29].
Although it has been generally accepted that 
acetaminophen is not associated with an increased
risk of adverse GI events, observational studies
report relative risks as high as 3.6 at high dosages
[28,29].
Threshold analysis of the models relating to
acetaminophen nonresponders indicates that when
effectiveness is deﬁned as GI events averted, rofe-
coxib is less costly than ibuprofen to treat patients
with a high risk of developing GI ulcers (around 14-
fold higher than the average NSAID user popula-
tion). This threshold value is higher when
effectiveness is deﬁned in terms of pain relief; that
is, rofecoxib is less costly than ibuprofen when
patients have 20-fold higher risk than the average
NSAID user population.
Analysis of the model was repeated with higher
estimates for both the probability of a conﬁrmed
PUB for acetaminophen (.009) and the probability
of PUB complications from acetaminophen (.0035)
to examine whether or not the higher estimates
from recent observational studies were likely to
impact our baseline results. When efﬁcacy was
deﬁned as GI events averted, we found that aceta-
minophen continues to be the least costly and most
effective, dominating the other options. When efﬁ-
Table 2 Base-case total costs, effectiveness, and incremental CE of different therapeutic strategies in a hypothetical cohort
of 1000 OA patients followed for 6 months for effectiveness deﬁned as adverse events averted and pain efﬁcacy
Effectiveness = adverse events averted Effectiveness = patients achieving MPCI response
Incremental CE ratio Incremental CE ratio
Acetaminophen Acetaminophen
Strategy Cost ($) Effectiveness All patients* nonresponders Effectiveness All patients nonresponders
Acetaminophen 63,000 994.9 750
Ibuprofen 112,000 979.5 Dominated NA 830 610.77 NA
Rofecoxib 471,000 990.8 Dominated 31,798.01 860 11,977.25 11,977.25
Celecoxib 474,000 990.3 Dominated Dominated 790 Dominated Dominated
Ibuprofen with 556,000 987.7 Dominated Dominated 830 Dominated Dominated
prophylaxis
*The difference in cost divided by the difference in effectiveness for each therapeutic strategy compared with the next best nondominated strategy. Dominance
occurs when one strategy is always less costly and more effective than the others.
Note: Results are shown separately for all patients and for acetaminophen nonresponders.
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cacy was deﬁned in terms of pain relief, once again,
acetaminophen was least costly; ibuprofen had an
incremental CE ratio of $534 per additional MPCI
response relative to acetaminophen.
Probabilistic sensitivity analysis [49] was con-
ducted using the Monte Carlo method to repeat the
simulation 10,000 times with a different set of ran-
domly generated parameters drawing each parame-
ter from a triangular prior distribution for each
simulation. The resulting distribution of effective-
ness and cost estimates (summarized in Table 3)
captures the global effect of uncertainty about all
model parameters.
The Monte Carlo simulation results of mean CE
ratios, their distributions, and the percentage of
each strategy is most likely to be the optimal choice
of the decision maker’s willingness to pay (WTP) for
any incremental improvement in outcome (Table 3).
In this analysis, we deﬁned the dollar amounts that
decision makers would be willing to pay for each
GI event averted or for each person achieving an
MPCI response. In probabilistic sensitivity analysis,
a therapy is most likely to be optimal or preferred
when it has the highest net health beneﬁt of all 
therapies in the greatest proportion of the 10,000
simulated trials. As decision makers’ value of
improvement in outcomes changes, so does the net
health beneﬁt of each treatment relative to the
others. Therefore, in the probabilistic sensitivity
analysis, the determination of the “most-likely to be
optimal” therapy depends on the value of averting
adverse events or pain improvement.
Table 3 indicates that when effectiveness was
deﬁned as the number of GI events averted, aceta-
minophen had the highest average net health beneﬁt
in 100% of the Monte Carlo simulations and there-
fore was most likely to be optimal for all patients,
regardless of WTP. For acetaminophen nonrespon-
ders, ibuprofen was most likely to be optimal (100
and 80% optimal) when WTP for averting a GI
event was $5,000 and $15,000, respectively, and
borderline (50.9% optimal) when WTP for avert-
ing a GI event was $25,000. Ibuprofen was sur-
passed by rofecoxib when WTP exceeded $35,000.
For effectiveness deﬁned in terms of pain relief,
when WTP per patient achieving MPCI was $300,
ibuprofen was optimal in approximately 56.2% of
the Monte Carlo simulations. For acetaminophen
nonresponders, when WTP per patient achieving
MPCI increased to $15,000, rofecoxib was optimal
in 52.3% of the simulations, and at $25,000, rofe-
coxib was optimal in 70% of the simulations.
A CE acceptability curve generated from proba-
bilistic sensitivity data, showing the thresholds of
decision-makers’ value at which different therapies
become most likely preferred (or optimal), is 
Table 3 Results of probabilistic sensitivity analysis using 10,000 Monte Carlo simulations
% Optimal at willingness to pay*
Acetaminophen Acetaminophen 
responders nonresponders
Strategy Mean SD Minimum Maximum $0 $300 $5,000 $15,000 $25,000
Effectiveness = adverse events averted
Acetaminophen 993.2 1.82 984.85 997.23 100 100 NA† NA† NA†
Ibuprofen 974.52 9.57 935.1 994.19 100 80.0 50.9
Ibuprofen with 986.94 5.39 958.09 997.65
prophylaxis
Rofecoxib 987.62 4.02 971.1 995.65 10.3 25.7
Celecoxib 987.78 4.04 971.79 996.12 8.9 23.0
Effectiveness = patients achieving MPCI response
Acetaminophen 743.41 24.69 680.73 799.86 96.7 43.8 NA† NA† NA†
Ibuprofen 833.47 14.47 800.23 869.88 3.3 56.2 98.8 47.6 29.9
Ibuprofen with 833.47 14.47 800.23 869.88
prophylaxis
Rofecoxib 860.07 16.36 820.99 899.48 1.2 52.3 70
Celecoxib 789.73 24.22 730.84 849.35 0.1 0.1
Costs ($, in thousands)
Acetaminophen 64.72 7.99 39.94 90.94
Ibuprofen 119.22 19.12 64.90 196.42
Ibuprofen with 556.58 13.82 519.09 623.40
prophylaxis
Rofecoxib 475.44 7.33 454.84 505.99
Celecoxib 477.29 7.40 456.60 507.07
*Refers the percentage of the 10,000 Monte Carlo trials in which the indicated strategy had the highest net health beneﬁt relative to all other strategies, when a
one unit improvement in effectiveness is valued at $0, $300, $5,000, $15,000, or $25,000.
† NA, not included in the analysis.
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presented in Fig. 2. Acceptability curves simultane-
ously assess the impact of uncertainty about 
parameter values and uncertainty about decision-
makers’ WTP for averting GI adverse events or pain
improvement [50]. This analysis (Fig. 2) is shown
only for effectiveness deﬁned as improvement in
pain, because acetaminophen was optimal for all
values of WTP when effectiveness was deﬁned as GI
adverse event averted.
The acceptability curves in Fig. 2 illustrate that
acetaminophen was most likely to be optimal only
when the value of an additional patient achieving
MPCI was less than $275. Ibuprofen was most
likely to be optimal until WTP exceeded $14,150,
after which rofecoxib became the most likely to be
optimal. It should be noted that the acceptability
curve thresholds for determining the therapy most
likely to be optimal ($275 and $14,150) differ from
the base-case incremental CE ratios ($610 and
$12,000). This difference occurs because the trian-
gular distributions chosen for the random parame-
ters in the probabilistic sensitivity analysis were
asymmetric, so that the average parameter value in
the probabilistic sensitivity analysis did not neces-
sarily equal the base-case parameter value.
Discussion
Our objective was to illustrate the trade-offs in the
costs and effectiveness of different drug options to
treat a cohort of patients with OA over 6 months,
speciﬁcally the incremental costs versus beneﬁts of
choosing the more recent therapeutic options over
the current standard for treatment (NSAIDs with
and without misoprostol and acetaminophen). Both
adverse events averted and pain efﬁcacy were used
as measures of effectiveness, ﬁrst on a model includ-
ing all patients and then on a subset of patients for
whom acetaminophen failed to provide adequate
pain relief and was therefore excluded from the
analysis.
Our analyses indicated that acetaminophen was
the least toxic and the cheapest option and there-
fore the most cost-effective in averting major
adverse events. It was also the most cost-effective 
in providing pain relief for OA patients. Aceta-
minophen remained the most cost-effective alterna-
tive even when we assumed an increased risk (i.e.,
twice the baseline estimate) of developing adverse
GI events at high doses, as suggested by a recent
observational study [28]. A switch to rofecoxib, the
most effective drug at reducing pain, would come
at considerable additional expense for patients who
would otherwise respond to acetaminophen. These
ﬁndings are consistent with the ACR recommenda-
tions [5].
Our analyses indicated that for patients who did
not respond to acetaminophen, ibuprofen was the
most cost effective in averting adverse GI events as
well as in relieving pain, but these results were sen-
sitive to a patient’s relative risk of developing a GI
adverse event. Our ﬁndings suggested that in high-
risk patients (more that 14-fold higher than the
average NSAID user population), rofecoxib was
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Figure 2 CE acceptability curves showing the values at which each of the therapeutic options becomes the optimal choice when effective-
ness is deﬁned as pain improvement.
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more cost-effective than ibuprofen with or without
misoprostol. Such patient groups include the elderly
with multiple risk factors such as multiple con-
comitant medications and history of GI problems
including ulcers or bleeds. Taken together, these two
ﬁndings underscore the need to carefully rule out
acetaminophen and ibuprofen as treatment options
before considering more costly alternatives. The
latter agents should only be considered for patients
at very high risk for ulcer perforations or bleeds
(Fig. 3).
The generic prices of acetaminophen and ibupro-
fen give these drugs a considerable advantage over
the newer drugs. Our ﬁndings also indicated that
the newer drugs, rofecoxib, celecoxib, and miso-
prostol, which cost approximately seven times that
of the generic version of acetaminophen and
ibuprofen, generated much less expenditure in treat-
ment of the GI adverse events than those associated
with ibuprofen. These drugs are only indicated for
patients who are at very high risk of these adverse
events, balancing the additional expense of drug
costs with costs of treating adverse events.
The strength of our study lies in the use of a 
previously published decision model [10], which
reﬂected the actual management of patients with
clinically suspicious or conﬁrmed upper GI compli-
cations, enrolled in a large-scale multicenter trial.
Another strength of our study was the high quality
of clinical and epidemiologic sources of probability
estimates. The probability estimates used to inform
the model were based on a comprehensive review
of recent randomized controlled trials and observa-
tional studies. Pooled estimates were also used
where available making results more widely gener-
alizable to a broader range of patients, drug uti-
lization patterns, and practice settings. Further, we
used estimates of actual resource utilization rather
than charges or expert opinions to assess costs. For
a very small part of our tree, where data was
unavailable, resource use was imputed from the
published literature by making a few modeling
assumptions. As far as possible, our sensitivity
analyses incorporated the range of plausible esti-
mates obtained from the literature.
The ﬁndings from our analyses both complement
and extend the conclusions of previous studies
examining the CE of these drugs. We compared our
methodology and ﬁndings with those from the six
published CE studies [51–56] addressing similar
research questions. Two of these analyses were con-
ducted in the United States [51,52], one in Canada
[53], one in Switzerland [54], one in Sweden [55],
and one in Norway [56]. The models used were
largely the same as ours. The major differences
between the models were the comparator drugs
used in the models. Only Holzer et al. [51] exam-
ined acetaminophen, but they did not consider the
COX-2 inhibitors.
Our ﬁndings are similar to those of Holzer et al.
[51], which showed that acetaminophen was the
least costly and most cost-effective alternative com-
pared to NSAIDs with and without the use of GPAs.
Our ﬁndings are also similar to Motheral et al. [52],
who reported rofecoxib to be the most cost-effec-
tive relative to NSAIDs when acetaminophen was
not included in the analysis. However, the time
horizon of their model was 3 months. We also could
not assess whether the drug costs in their model
included the cost of GPAs to prevent ulcers, similar
to the role of misoprostol in our model. Our ﬁnd-
ings are also similar to those of Zabinski et al. [53],
where NSAIDs were found to be more cost-
effective than celecoxib, which in turn was more
cost-effective than the NSAIDs plus GPAs. In con-
trast, the ﬁndings of Chancellor et al. [54], Haglund
and Svarvar [55], and Svarvar and Aly [56] indi-
cated that celecoxib was the most cost-effective.
The divergent ﬁndings of these latter studies could
be attributable to differences in efﬁcacy and toxic-
ity estimates and possibly differences in the national
health systems in which these studies were 
conducted.
Generic acetaminophen is most cost-effective, in
terms of GI toxicity, to treat OA patients irrespec-
tive of the risk of GI ulcers, supporting the current
guidelines for OA drug therapy. Ibuprofen is the
least costly for patients who do not respond to
acetaminophen; typically those patients with more
severe pain. Rofecoxib is cost-effective for patients
who both are at a higher risk of GI events and do
not respond to acetaminophen (Fig. 3).
Our analysis is unique in two ways. First, we
attempt to examine two outcomes, one of which to
our knowledge has not previously been examined
in economic analysis for OA, that is, pain relief.
This strategy enables us to compare the incremen-
Type of OA patient 
All Acetaminophen 
nonresponders 
Low Acetaminophen Ibuprofen
High Acetaminophen Rofecoxib 
Risk of
GI Ulcers 
Figure 3 Decision grid based on CE ﬁndings.
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tal CE ratios for both measures of effectiveness.
Second, our model examines a spectrum of drugs,
including the ones recommended by ACR—that is,
acetaminophen as a ﬁrst line of treatment and the
newer COX-2 inhibitors for patients at high risk of
perforations, ulcers or bleeds. This enabled us to
analyze the threshold risk level at which it becomes
more cost-effective to use the newer drugs.
Our primary analysis focused on an OA patient
cohort where the ACR recommends acetaminophen
as the ﬁrst-line treatment. Except for Holzer et al.
[51], none of the other CE studies included aceta-
minophen as the drug of choice. In addition, all
models assumed equal pain relief across arms. Ours
does not because there is good evidence supporting
differences in pain efﬁcacy and patient preferences
between acetaminophen and the other drugs used
in the model [36,57,58]. In our study, we use pain
relief as an outcome measure, like studies in
rheumatoid arthritis. We also analyzed the drugs
indicated for higher pain relief separately because
of the different scale in the costs of these drugs. We
were thus able to assess the CE for different patient
populations (all patients vs. acetaminophen nonre-
sponders; Fig. 3).
These results, however, must be interpreted in
light of certain limitations:
• First, we used a static, deterministic model to
analyze the series of events over 6 months. A
Markov model could have been useful in
extending the ﬁndings of this study to a longer
period, while at the same time taking into
account patient compliance with drug therapy,
switches between drugs [59], and long-term
adverse effects. However, our probability esti-
mates were derived from the existing literature
and, therefore, limited to the duration of studies.
Unfortunately, no long-term data are available
to inform a Markov model.
• Second, we limited our analysis to direct medical
costs over a 6-month period. Again, because of
the absence of data, a more comprehensive cost
analysis was not feasible.
• Third, the use of mostly clinical trial data may
be a source of bias in estimating effectiveness as
well as the true incidence of drug-related adverse
events in the community. Patients enrolled in 
such trials may differ in important ways from
population-based cohorts of patients with OA,
thus introducing a potential referral bias. Thus,
probability and cost estimates derived from
trials may be biased. However, large trials (such
as VIGOR and CLASS) more closely reﬂect the
real-life setting than smaller clinical trials. In
addition, we used data from observational
studies to provide estimates for the ranges for
sensitivity analyses.
• Fourth, there is a need for a preference-based
utility measure for OA that combines toxicity
and effectiveness in pain relief outcomes in a
single scale. This is an area for potential future
research.
• Fifth, we did not include in our model other
potentially important adverse events, focusing
instead on GI adverse events. Although recent
data on rofecoxib and celecoxib suggest the
importance of hepatic, renal, and cardiovascu-
lar adverse events, it is unclear to what degree
the renal and hepatic laboratory abnormalities
would manifest clinically and generate resource
utilization. Moreover, the incidence of severe
hepatic and renal disease is very low [60]
(<1/1000 person-years) making these events rel-
atively less inﬂuential from a CE point of view
compared with GI adverse events. Regarding
common and less severe forms of hepatic and
renal adverse events (e.g., lab abnormalities), it
is almost impossible to obtain exactly compara-
ble data (inclusion of the same adverse events)
across drugs. Cardiovascular adverse events
would have been important to include from a
CE point of view because the prevalence is high
among the elderly. Evidence and quantitative
ﬁndings for thrombotic cardiovascular events
have been documented in the context of VIGOR
and CLASS studies but quantitative data for
similar events are scanty for NSAIDs and aceta-
minophen [61]. Inclusion of these adverse events
is an important area for future research.
• Finally, recent evidence strengthens the value 
of Helicobacter pylori eradication in reducing
NSAID related GI toxicity [62,63], and eradica-
tion strategies need to be incorporated into
future CE analyses.
In summary, our results suggest that for OA
patients, acetaminophen dominates the other thera-
pies in terms of cost per GI event averted, support-
ing the current guidelines for OA drug therapy. In
terms of CE acceptability for average-risk patients
who did not respond to acetaminophen, rofecoxib
is preferred to ibuprofen only if the value of avoid-
ing a GI event exceeds $30,000. In terms of pain
control, if the value of pain relief is below $275 per
patient achieving MPCI, acetaminophen is pre-
ferred; between $275 and $14,150, ibuprofen is pre-
ferred; and above $14,150, rofecoxib is preferred.
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